12An investigation for investors in NASDAQ:AGIO shares was announced concerning possible violations of securities laws by Agios Pharmaceuticals and certain of its directors and officers.
Shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) declined from $67.25 per share in November 2016 to as low as $40.50 per share on January 10, 2017.
Investors who purchased shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on whether certain statements by Agios Pharmaceuticals Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Agios Pharmaceuticals Inc reported that its annual Total Revenue declined from $65.36 million in 2014 to $59.12 million in 2015 and that its Net Loss increased from $53.50 million in 2014 to $117.73 million in 2015.
At the 2016 American Society of Hematology meeting btween December 3 and 6, 2016, Agios Pharmaceuticals Inc presented new data for its AG-348 and AG-519 molecules, in development for treatment of pyruvate kinase deficiency.
Agios Pharmaceuticals Inc reportedly stated that a case of Grade 2 thrombocytopenia (a reduction of platelets in blood cells) was reported in a patient receiving AG-519, and that an ongoing severe adverse event of drug-related cholestatic hepatitis was observed in a bioavailability and food effect study after a dose of 300 mg.
Those who purchased NASDAQ:AGIO shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com
Leave Your Comments